Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. J of Skin [Internet]. 2024 Nov. 18 [cited 2026 Mar. 17];8(6):s423. Available from: https://skin.dermsquared.com/skin/article/view/3090